Drug Search Results
More Filters [+]

Avadomide

Alternative Names: avadomide, cc-122, cc122, cc 122
Latest Update: 2024-09-23
Latest Update Note: Clinical Trial Update

Product Description

Avadomide (CC_122) is a novel cereblon_binding agent that exhibits antilymphoma and immune_modulation activities with a biological profile distinct from similar agents, such as lenalidomide.Ê (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780008/)

Mechanisms of Action: CRBN Modulator,IKZF1 Inducer,IKZF3 Inducer

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Avadomide

Countries in Clinic: Belgium, France, Italy, Japan, Netherlands, Spain, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Diffuse Large B-Cell Lymphoma|Glioblastoma|Lymphoma, Non-Hodgkin|Multiple Myeloma|Primary Central Nervous System Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CA092-1000

P1

Active, not recruiting

Lymphoma, Non-Hodgkin

2026-02-25

28%

CC-122-ST-001

P1

Completed

Glioblastoma|Multiple Myeloma|Primary Central Nervous System Lymphoma|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin

2023-11-21

Recent News Events